Filtered By:
Source: American Heart Journal
Condition: Heart Disease

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 47 results found since Jan 2013.

Diabetes, diabetes severity and coronary heart disease risk equivalence REasons for Geographic and Racial Differences in Stroke (REGARDS)
Conclusions Participants with diabetes had lower risk of CHD events than those with prevalent CHD. However, participants with severe diabetes had similar risk as those with prevalent CHD. Diabetes severity may need consideration when deciding whether diabetes is a CHD risk equivalent.
Source: American Heart Journal - August 11, 2016 Category: Cardiology Source Type: research

Comparison of Risk Scores for the Prediction of Stroke in African Americans: Findings from the Jackson Heart Study
Conclusions Both scores were associated with incident stroke in a dose–response fashion; however, the CVD risk model was more discriminating than the CVH model. The CVH score may still be preferable for its simplicity in application to broad patient populations and public health efforts.
Source: American Heart Journal - April 16, 2016 Category: Cardiology Source Type: research

Cardiovascular health among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos Results
Conclusions Hispanic/Latino LS7s compared favorably with existing national estimates; however, we found areas for improvement. Several Hispanic/Latino LS7 strengths and weaknesses varied by sex and heritage, providing important information to guide targeted health promotion efforts toward achieving 2020 goals.
Source: American Heart Journal - February 20, 2016 Category: Cardiology Source Type: research

Design and Rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) Trial
Conclusions The EUCLID study is investigating whether treatment with ticagrelor versus clopidogrel, given as antiplatelet monotherapy, will reduce the incidence of cardiovascular and limb-specific events in patients with symptomatic PAD.
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research

Reducing cardiovascular risk through treatment of obstructive sleep apnea: 2 methodological approaches
This article describes 2 independent studies that worked collaboratively to fill these gaps. The populations, design features, and relative benefits/challenges of the 2 studies (SleepTight and BestAIR) are described. Both studies were encouraged to have multidisciplinary teams with expertise in behavioral interventions to improve PAP compliance. Both studies provide key information that will be useful to the research community in future large-scale, event-driven, randomized trials to evaluate the efficacy and/or effectiveness of strategies to identify and treat significant OSA for decreasing risk of major adverse cardiovas...
Source: American Heart Journal - December 22, 2015 Category: Cardiology Source Type: research

Individual Components of the Romhilt-Estes Left Ventricular Hypertrophy Score Differ in Their Prediction of Cardiovascular Events: the Atherosclerosis Risk in Communities (ARIC) Study
Conclusions The R-E score is predictive of CVD outcomes. The six R-E score components differ in their associations with different CVD outcomes, indicating that they may be electrical biomarkers of different physiological events within the myocardium. Graphical abstract
Source: American Heart Journal - October 4, 2015 Category: Cardiology Source Type: research

Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study
Conclusions Lower circulating levels of sRAGE are independently associated with the development of heart failure in a community-based population. Our results add to the growing evidence that sRAGE is a valuable predictor of cardiovascular disease.
Source: American Heart Journal - September 30, 2015 Category: Cardiology Source Type: research

Reducing Cardiovascular Risk through Treatment of Obstructive Sleep Apnea: Two Methodological Approaches
Publication date: Available online 11 September 2015 Source:American Heart Journal Author(s): Klar Yaggi, Murray A. Mittleman, Dawn M. Bravata, John Concato, James Ware, Catherine M. Stoney, Susan Redline Obstructive sleep apnea (OSA) significantly impacts cardiovascular health, demonstrated by observational investigations showing an independently increased risk of ischemic heart disease, diabetes, hypertension, congestive heart failure, acute coronary syndrome, stroke, cardiovascular mortality, and all-cause mortality. Positive airway pressure (PAP), a medical therapy for sleep apnea, reverses airway obstruction ...
Source: American Heart Journal - September 11, 2015 Category: Cardiology Source Type: research

sRAGE and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study
Conclusions Lower circulating levels of sRAGE are independently associated with the development of heart failure in a community-based population. Our results add to the growing evidence that sRAGE is a valuable predictor of cardiovascular disease.
Source: American Heart Journal - August 14, 2015 Category: Cardiology Source Type: research

Genetic Mutations in African Patients with Atrial Fibrillation: Rationale and Design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL)
Conclusion This is the first study determining genetic associations in valvular and non-valvular atrial fibrillation in sub-Saharan Africa with a control population. The results advance knowledge about atrial fibrillation and will enhance international efforts to decrease atrial fibrillation-related morbidity.
Source: American Heart Journal - June 16, 2015 Category: Cardiology Source Type: research

Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality
Conclusions Large increases or sustained elevations in hs-CRP over a six-year period were associated with a subsequent increased risk of diabetes; and persons with sustained elevations in hs-CRP were at the highest risk of CVD and mortality. Two measurements of hs-CRP are better than one for characterizing risk and large increases are particularly prognostic.
Source: American Heart Journal - April 22, 2015 Category: Cardiology Source Type: research

Antistreptokinase antibodies and outcome of fibrinolytic therapy with streptokinase for left-sided prosthetic valve thrombosis
Conclusion Anti-SK antibody titers are not associated with success of fibrinolytic therapy using SK in patients with left-sided PVT.
Source: American Heart Journal - November 17, 2014 Category: Cardiology Source Type: research

Anti-streptokinase antibodies and outcome of fibrinolytic therapy with streptokinase for left-sided prosthetic valve thrombosis
Conclusion Anti-SK antibody titres are not associated with success of fibrinolytic therapy using SK in patients with left-sided PVT.
Source: American Heart Journal - October 31, 2014 Category: Cardiology Source Type: research

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Publication date: Available online 7 August 2014 Source:American Heart Journal Author(s): Gregory G. Schwartz , Laurence Bessac , Lisa G. Berdan , Deepak L. Bhatt , Vera Bittner , Rafael Diaz , Shaun G. Goodman , Corinne Hanotin , Robert A. Harrington , J. Wouter Jukema , Kenneth W. Mahaffey , Angèle Moryusef , Robert Pordy , Matthew T. Roe , Tyrus Rorick , William J. Sasiela , Cheerag Shirodaria , Michael Szarek , Jean-François Tamby , Pierluigi Tricoci , Harvey White , Andreas Zeiher , Philippe Gabriel Steg Following acute coronary syndrome (ACS), the risk for future cardiovascular events is high and is related to le...
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Conclusions LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research